GigaGen is a venture-backed pre-clinical biotherapeutics company based in the San Francisco Bay Area. Our team is comprised of innovative professionals with a proven track record of converting ground-breaking science into life-changing medicine. Our science captures the genetic make-up of the entire human immune repertoire, characterizing B and T cells at a rate of millions per hour, while simultaneously identifying the antigens and proteins they bind to. It is our mission to discover and develop novel T cell, monoclonal antibody, and polyclonal antibody therapies that improve outcomes for patients with severe disease. Biotherapeutics derived from natural immune repertoires mimic the body's natural immune system - they can be more effective, can have fewer side effects, and can have faster development timelines than those developed from traditional methods.